P-115: Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)

Renal impairment (RI) is a common complication of multiple myeloma (MM) and has been associated with poor survival. MIR50 is an observational, prospective, multicenter study aimed to evaluate the renal response (RR) to treatment in patients (pts) with RRMM. Renal and MM responses are evaluated accor...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2021-10, Vol.21, p.S97-S98
Main Authors: Garcia-Guiñón, Antonio, Morales, Enrique, Sureda, A, González-García, Esther, Durán, María Soledad, Escalante, Fernando, Gironella, M, González-López, Tomás José, Duro, Rafael, Encinas, Manuel Pérez, Ribas, Paz, Cabezudo, Elena, García, Rafael Lluch, Español, Ignacio, Cabanas, Valentín, García-Muñoz, Ricardo, Márquez, José Antonio, Navarro, Mireya, de la Rubia, Javier
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal impairment (RI) is a common complication of multiple myeloma (MM) and has been associated with poor survival. MIR50 is an observational, prospective, multicenter study aimed to evaluate the renal response (RR) to treatment in patients (pts) with RRMM. Renal and MM responses are evaluated according to IMWG criteria in pts with moderate RI (mRI;CrCl 30–50mL/min) or severe RI (sRI;CrCl
ISSN:2152-2650
2152-2669
DOI:10.1016/S2152-2650(21)02242-4